Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
The effects of sequential therapy with ancrod followed by streptokinase are reported in a series of patients with thrombotic disease. Measurements have been made in blood coagulation, fibrinolysis and whole blood and plasma viscosity. Intravenous infusion of ancrod resulted in a significant reduction in plasma fibrinogen which was associated with highly significant reduction in both plasma and whole blood viscosity. Sequential therapy with streptokinase resulted in a gradual rise in fibrinogen and a slight but significant rise in whole blood and plasma viscosity. All patients showed clinical improvement and no haemorrhagic complications resulted.
D000721:Ancrod / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D001809:Blood Viscosity; D010450:Endopeptidases / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D010958:Plasminogen / Q000032:analysis; D012212:Rheology; D012709:Serum Albumin / Q000032:analysis; D012712:Serum Globulins / Q000032:analysis; D013300:Streptokinase / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy*; D013997:Time Factors
D005338:Fibrin Fibrinogen Degradation Products; D012709:Serum Albumin; D012712:Serum Globulins; D005340:Fibrinogen; D010958:Plasminogen; D010450:Endopeptidases; D013300:Streptokinase; D000721:Ancrod